A Study of a Mobile Phone Application Measuring the Eyes Before and After Medication

N/A Completed NCT06629740

Summary

This is a post-market clinical follow-up study on an approved CE-marked eHealth system where a mobile phone application is used to measure the pupils and eye measurements to monitor the use of different drug substances. The goal of the study is to collect additional information when using the system and to improve the current models for indicating the use of cannabinoids and phenethylamines. Drug intake of cannabinoid or phenethylamine will in this study be simulated using two commonly used medicines. The study will include healthy volunteers where each participant will participate in the study for approximately 10 days. The participant will be using the mobile phone application for about a week, first at the clinic and then in the home environment. After approximately a week the participant will visit the clinic to be administered with the selected medicine whereafter the mobile phone application will be used for up to 5 hours. A final phone call will be taken place at approximately day 10, whereafter the participant has completed the study.

Verify if Self-administered Eye Scanning Using a Mobile Phone Application, Using Native Key Features (Alone or in Predefined Combination(s)), Can Indicate Use of Each Medicine (D1-D2).

Day 7 (+/- 2 days) · Key features

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

• Brain Energy for Amyloid Transformation in Alzheimer's Disease Study — Wake Forest University Health Sciences
• Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss — Eli Lilly and Company
• Using a Wireless Controller to Deliver a Lighting Intervention to Persons With Dementia — Icahn School of Medicine at Mount Sinai
• Deprescribing in Patients Living With Dementia With Caregiver and Provider Nudges — Brigham and Women's Hospital
• Technology and Family Thriving Study — University of California, Santa Barbara
• Community-based Brain Health Program to Address Dementia Risk — Posit Science Corporation

All trials